

# Invitation

3<sup>rd</sup> Northern European Multidisciplinary RCC Meeting (NEMDRCC)

Copenhagen June 15<sup>th</sup> and 16<sup>th</sup> 2018



I am interested to join the Morthern European Multidisciplinary RCC meeting in Copenhagen 15th and 16th of June 2018



# 3<sup>rd</sup> Northern European Multidisciplinary RCC Meeting (NEMDRCC)

Copenhagen June 15th and 16th 2018

It is with great pleasure we are able to invite to the 3<sup>rd</sup> Northern European Multidisciplinary RCC meeting at Phoenix Hotel in Copenhagen, June 15<sup>th</sup> and 16<sup>th</sup> 2018 (www.phoenixcopenhagen.dk). The hotel is located in the center of Copenhagen and is easily accessible from the airport and metro.

The focus of the RCC meetings is to bring together oncologists, urologists, pathologists, radiologists, and scientists involved in clinical and research aspects of renal cell carcinoma. Therefore, the 3rd Northern European Multidisciplinary RCC meeting will provide a multidisciplinary forum for the exchange of ideas and information for research and treatment of RCC. During the meeting, adequate time is allocated for Q & A and discussions, enabling high participant involvement.

A special focus of the meeting is to stimulate interest in RCC from "next-generation" doctors and researchers. Therefore, the organizing committee encourages the attendance of younger doctors and researchers in the meeting. All attendees are encouraged to submit an abstract (e.g. current research or a real-life clinical case report), and the best abstracts will be selected for oral presentations.

Having both junior and senior doctors out of the hospital at the same time, the meeting must take place outside of normal working hours. We therefore welcome you to Copenhagen for a Friday-night-Saturday-morning meeting in the middle of Copenhagen for an informative and informal meeting.

Pfizer provides funding and infrastructure for the meeting but is not involved in the scientific program.

The program is made by an independent scientific planning committee:

Frede Donskov (DK) Chairman Bjarne Kromann (DK) Petri Bono (FI) Ulrika Harmenberg (SE) Christoph Müller (NO) Börje Ljungberg (SE) Benoit Beuselinck (BE)

If you have any questions or need further information, please contact Maurits Blesgraaf (Maurits. Blesgraaf@pfizer.com) or Nadja van de Kraats (Nadja.Vandekraats@pfizer.com)

Best regards on behalf of the Planning Committee and Pfizer Oncology

## Program Friday June 15th

16.30 - 17.00 **Sandwich** 

17.00 - 17.05 **Welcome remarks** 

 ${\it Frede\ Donskov}, {\it Denmark}$ 

Chairman: Börje Ljungberg, Sweden

#### Impact of local control - current challenges:

and cryoablation

17.05 - 17.30	Impact of cytoreductive nephrectomy in synchronous metastatic RCC	Christian Beisland, Norway
17.30 - 17.55	Open, laparoscopic or robotic- assisted partial nephrectomy for RCC. Does lymphadenectomy have a place?	Nessn Azawi, Denmark
17.55 - 18.15	Cryoablation for small renal masses	Tommy Kjærgaard Nielsen, Denmark
18.15 - 18.35	Q & A - discussion about surgery	

#### Clinical trial report:


18.35 - 18.50	Spinal analgesia improves surgical	Börje Ljungberg,
	outcome after open nephrectomy	Sweden
	for renal cell carcinoma	

#### Update from DaRenCa - the Danish Renal Cancer Study Group:

18.50 - 19.00	A new tool to register recurrent	Bjarne Kromar
	RCC, and curative intended	Andersen, Den
	treatments.	

#### Oral abstract presentations:

19.00 - 19.10	Oral abstract - presenter to be selected from submitted abstracts
19.10 - 19.20	Oral abstract - presenter to be selected from submitted abstracts
19.20 - 19.30	Oral abstract - presenter to be selected from submitted abstracts
10.30	Dinner & networking



### Program Saturday June 16th

.00 Breakfast

Chairman: Benoit Beuselinck, Belgium

#### Keynote speaker:

### 8.45 - 8.50 Q & A - discussion

# From bench to clinic - and from clinic to bench: 8.50 - 9.10 Genetic polymorphisms and Bench:

sunitinib pharmacokinetics and

	p	
9.10 - 9.15	Q & A - discussion	
9.15 - 9.25	Oral abstract - presenter to be selected from submitted abstracts	
9.25 - 9.55	Coffee break	
9.55 - 10.15	Update on select adjuvant clinical trials: What to do?	Frede Donskov, Denmark
10.15 - 10.25	Discussion	
10.25 - 10.40	Prognostic role of neutrophil- lymphocyte ratio in RCC	Maria Møller Peders Denmark

Benoit Beuselinck,

Laurence Albiges,

Belgium

# Survival update in the nordic countries:

10.40 - 10.50	Overall survival in renal cell carcinoma after introduction of targeted therapies: a Norwegian population-based study	Jan Oldenburg, Norway
10.50 - 11.00	Overall survival in renal cell carcinoma after introduction of targeted therapies: a Swedish population-based study	Magnus Lindskog, Sweden
11.00 - 11.05	Discussion	
11.05 - 11.30	Coffee break	

#### Current clinical challenges in mRCC: 11.30 - 12.05 Check-point inhibitors in RCC.

	Efficacy, toxicity and subsequent therapy	France
12.05 - 12.15	Q & A - discussion	
12.15 - 12.30	The predictive value of expression profiling in metastatic ccRCC undergoing metastasectomy	Annelies Verbiest, Belgium

# Oral abstract presentations:

12.30 - 12.40	Oral abstract - presenter to be selected from submitted abstracts
12.40 - 12.50	Oral abstract - presenter to be selected from submitted abstracts
12.50 - 13.00	Oral abstract - presenter to be selected from submitted abstracts
13.00	Closing remarks Frede Donskov, Denmark
13.05 - 14.00	Lunch & networking



I am interested to join the Morthern European Multidisciplinary RCC meeting in Copenhagen 15<sup>th</sup> and 16<sup>th</sup> of June 2018

